Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. 2013

Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710 ; Department of Pathology, Duke University Medical Center, Durham, NC 27710.

A major mechanism by which human regulatory T cells (T(regs)) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T(regs) also possess the capacity to kill tumor cells using similar mechanisms. Bispecific antibodies (bscAbs) have emerged as a promising class of therapeutics that activate T cells against tumor antigens without the need for classical MHC-restricted TCR recognition. Here, we show that a bscAb targeting the tumor-specific mutation of the epidermal growth factor receptor, EGFRvIII, redirects human CD4(+)CD25(+)FoxP3(+) T(regs) to kill glioblastoma (GBM) cells. This activity was significantly abrogated by inhibitors of the granzyme-perforin pathway. Notably, analyses of human primary GBM also displayed diffuse infiltration of granzyme-expressing FoxP3(+) T cells. Together, these data suggest that despite their known suppressive functions, tumor-infiltrating T(regs) possess potent cytotoxic mechanisms that can be co-opted for efficient tumor cell lysis.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D050378 T-Lymphocytes, Regulatory CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells. Regulatory T Cell,Regulatory T-Cell,Regulatory T-Lymphocyte,Regulatory T-Lymphocytes,Suppressor T-Lymphocytes, Naturally-Occurring,T-Cells, Regulatory,Th3 Cells,Tr1 Cell,Treg Cell,Regulatory T-Cells,Suppressor T-Cells, Naturally-Occurring,Tr1 Cells,Treg Cells,Cell, Regulatory T,Cell, Th3,Cell, Tr1,Cell, Treg,Cells, Regulatory T,Cells, Th3,Cells, Tr1,Cells, Treg,Naturally-Occurring Suppressor T-Cell,Naturally-Occurring Suppressor T-Cells,Naturally-Occurring Suppressor T-Lymphocyte,Naturally-Occurring Suppressor T-Lymphocytes,Regulatory T Cells,Regulatory T Lymphocyte,Regulatory T Lymphocytes,Suppressor T Cells, Naturally Occurring,Suppressor T Lymphocytes, Naturally Occurring,Suppressor T-Cell, Naturally-Occurring,Suppressor T-Lymphocyte, Naturally-Occurring,T Cell, Regulatory,T Cells, Regulatory,T Lymphocytes, Regulatory,T-Cell, Naturally-Occurring Suppressor,T-Cells, Naturally-Occurring Suppressor,T-Lymphocyte, Regulatory,Th3 Cell
D053804 Granzymes A family of serine endopeptidases found in the SECRETORY GRANULES of LEUKOCYTES such as CYTOTOXIC T-LYMPHOCYTES and NATURAL KILLER CELLS. When secreted into the intercellular space granzymes act to eliminate transformed and virus-infected host cells. Cytotoxic Serine Protease B,Cytotoxic T-Lymphocyte Associated 1 Protein,Cytotoxic T-Lymphocyte Proteinase 1,Fragmentin 2,Granzyme,Granzyme A,Granzyme B,Granzyme C,Granzyme K,Granzyme M,Granzyme-3,Granzyme-Like Protein III,Hanukah Factor,NK-Tryptase-2,Natural Killer Cell Granule Tryptase-2,Cytotoxic T Lymphocyte Associated 1 Protein,Cytotoxic T Lymphocyte Proteinase 1,Granzyme 3,Granzyme Like Protein III,NK Tryptase 2,Natural Killer Cell Granule Tryptase 2
D054353 Perforin A calcium-dependent pore-forming protein synthesized in cytolytic LYMPHOCYTES and sequestered in secretory granules. Upon immunological reaction between a cytolytic lymphocyte and a target cell, perforin is released at the plasma membrane and polymerizes into transmembrane tubules (forming pores) which lead to death of a target cell. Cytolysin,Lymphocyte Pore-Forming Protein,Perforin 1,Lymphocyte Pore Forming Protein,Pore-Forming Protein, Lymphocyte
D018033 Antibodies, Bispecific Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors. Bifunctional Antibodies,Bispecific Antibodies,Bispecific Monoclonal Antibodies,Antibodies, Bifunctional,Antibodies, Bispecific Monoclonal,Monoclonal Antibodies, Bispecific

Related Publications

Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
February 2012, Journal of immunology (Baltimore, Md. : 1950),
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
January 2013, PloS one,
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
March 2015, Cancer immunology research,
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
December 2021, Journal of hematology & oncology,
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
November 2015, Current opinion in hematology,
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
January 2005, Cancer chemotherapy and biological response modifiers,
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
March 2008, Journal of immunology (Baltimore, Md. : 1950),
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
August 1978, Journal of immunology (Baltimore, Md. : 1950),
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
November 2017, JCI insight,
Bryan D Choi, and Patrick C Gedeon, and James E Herndon, and Gary E Archer, and Elizabeth A Reap, and Luis Sanchez-Perez, and Duane A Mitchell, and Darell D Bigner, and John H Sampson
October 2010, Immunology,
Copied contents to your clipboard!